Company intelligence / Profile preview
Axis Therapeutics Ltd.
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Early clinical studies in China with the HATac platform have demonstrated good safety profiles. The company focuses on developing next-generation immunotherapies for cancer using advanced engineered T-cell technologies.
- Therapeutic areas
- Oncology
- Modalities
- TCR-T cell therapy (T-cell receptor-engineered T cells)CAR-T cell therapy (Chimeric Antigen Receptor T cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Hong Kong Polytechnic University – Joint Center for Immunotherapy research collaborationPharmaEssentia – Research collaboration for development of TCR-T therapies in Taiwan
Beyond the preview
Go deeper on Axis Therapeutics Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axis Therapeutics Ltd..